Does USTEKINUMAB Cause Mobility decreased? 2,287 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 2,287 reports of Mobility decreased have been filed in association with USTEKINUMAB (PYZCHIVA). This represents 2.7% of all adverse event reports for USTEKINUMAB.
2,287
Reports of Mobility decreased with USTEKINUMAB
2.7%
of all USTEKINUMAB reports
1,457
Deaths
1,503
Hospitalizations
How Dangerous Is Mobility decreased From USTEKINUMAB?
Of the 2,287 reports, 1,457 (63.7%) resulted in death, 1,503 (65.7%) required hospitalization, and 1,508 (65.9%) were considered life-threatening.
Is Mobility decreased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for USTEKINUMAB. However, 2,287 reports have been filed with the FAERS database.
What Other Side Effects Does USTEKINUMAB Cause?
Drug ineffective (12,471)
Off label use (10,990)
Product dose omission issue (9,405)
Fatigue (5,457)
Product use issue (5,008)
Psoriasis (4,955)
Pain (4,872)
Rash (4,736)
Crohn's disease (4,662)
Arthralgia (4,608)
What Other Drugs Cause Mobility decreased?
ADALIMUMAB (8,829)
ETANERCEPT (8,321)
METHOTREXATE (5,936)
ABATACEPT (4,519)
TOCILIZUMAB (4,403)
LEFLUNOMIDE (4,354)
HYDROXYCHLOROQUINE (4,105)
RITUXIMAB (4,067)
INFLIXIMAB (3,784)
TOFACITINIB (3,734)
Which USTEKINUMAB Alternatives Have Lower Mobility decreased Risk?
USTEKINUMAB vs USTEKINUMAB-STBA
USTEKINUMAB vs VADADUSTAT
USTEKINUMAB vs VALACYCLOVIR
USTEKINUMAB vs VALBENAZINE
USTEKINUMAB vs VALBENAZINE DITOSYLATE